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Cytomegalovirus (CMV) retinitis is the most common 
opportunistic ocular infection in immunocompromised 
patients [1]. However, CMV retinitis can develop in immu-
nocompetent patients after an intravitreal triamcinolone 
acetonide (IVTA) or after implantation of fluorocinolone 
acetonide [2-6]. All patients with such problems have been 
successfully treated with intravitreal and/or intravenous, 
and oral administration of ganciclovir (Table 1). Sponta-
neous resolution of CMV retinitis has been reported in 
infants with congenital infection and in patients receiving 
highly active antiretroviral therapy (HAART); however, 
spontaneous resolution has not been previously reported in 
a patient with intravitreal steroid-induced CMV. Here we 
report such a case [7,8].
Case Report
A 73-year-old woman with a history of well-controlled 
type 2 diabetes mellitus and hypertension presented to 
the clinic with visual loss in both eyes in July 2008. The 
vision was 20 / 200 in both eyes. There were no other 
abnormalities in the anterior segments of the eyes, other 
than visually significant cataracts, bilaterally. The fundus 
examination with the indirect ophthalmoscope revealed 
the presence of a moderate nonproliferative diabetic reti-
nopathy and macular edema in both eyes. Optical coher-
ence tomography showed macular thickening in both eyes 
with a taut posterior hyaloid membrane of the macula in 
the right eye. In July of 2008, phacoemulsification and in-
traocular lens implantation were performed, as well as vit-
rectomy with removal of the posterior hyaloid and internal 
limiting membranes, as well as endolaser treatment of the 
right eye. At the end of the vitrectomy, IVTA (4 mg) was 
administered. One week later, phacoemulsification, intra-
ocular lens implantation, and IVTA administration (4 mg) 
were performed on the left eye. The postoperative clinical 
course was fair. In August of 2008, the vision improved 
slightly to 20 / 100 with improvement of the macular ede-
ma in both eyes.
Three-months later, in October of 2008, the patient pre-
sented with ‘cloudy vision’ in both eyes that developed two 
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A 73-year-old woman underwent vitrectomy and intravitreal triamcinolone acetonide (IVTA) of the right eye and 
cataract surgery with IVTA of the left eye, for bilateral diabetic macular edema. The patient presented with visual 
loss in both eyes three-months postoperatively. The fundoscopic examination revealed white-yellow, necrotic 
peripheral lesions in the superotemporal quadrant of both eyes. Although bilateral acute retinal necrosis was 
suspected, azotemia resulting from diabetic nephropathy limited the use of acyclovir. Antiviral treatment was 
not started. A sample of the aqueous humor for polymerase chain reaction (PCR) analysis was obtained. One 
week later, the PCR results indicated the presence of cytomegalovirus (CMV). Since the retinal lesions did 
not progress and did not threaten the macula, the patient was followed without treatment for CMV. The retinal 
lesions progressively regressed and completely resolved in both eyes by six months of follow-up. Patients with 
IVTA-induced CMV retinitis may not require systemic treatment with ganciclovir.
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weeks previously. The visual acuity was 20 / 200 in the 
right eye and counting fingers at 30 cm in the left eye. The 
intraocular pressure (IOP) was 30 mmHg in the right eye 
and 42 mmHg in the left eye. The slit lamp examination 
demonstrated fine keratic precipitates of the corneal en-
dothelium, 3+ inflammatory cells, 2+ flare in the anterior 
chamber, and moderate vitreous haze in both eyes. The 
fundus examination revealed white-yellow, necrotic pe-
ripheral retinal lesions in the superotemporal quadrant of 
both eyes (Fig. 1A and 1B).
As bilateral acute retinal necrosis was suspected, start-
ing intravenous treatment with acyclovir was considered. 
However, the patient refused hospital admission and fur-
ther treatment. Moreover, azotemia resulting from diabetic 
Table 1. Previous reports of CMV retinitis after IVTA
Age 
(yr) Sex Systemic 
disease
Ocular 
pathology
Previous 
Ocular 
surgery
Onset of 
CMV retinitis 
following IVTA 
(mon)
Initial 
VA
Final 
VA Treatment
Saidel et al. [2]
Am J Ophthalmol 
2005
75 M DM DME – 4 0.05 0.05 Diagnostic vitrectomy with intravitreal 
ganciclovir (2 mg), vancomycin (1 mg), 
ceftazicidime (2.25 mg)
Oral valganciclovir 900 mg twice daily for 9 
months
Repeated intravitreal ganciclovir (2.0 mg), 
twice
After recurrence
Repeated intravitreal ganciclovir (2.0 mg), 
once
Oral valganciclovir
Delyfer et al. [3]
Acta Ophthalmol 
Scand   
2007
77 M DM AMD IOL 3 FC
1.8 m
0.1 Intravitreal ganciclovir (2 mg)
Intravenous ganciclovir (5 mg/kg/12 hr) for 
1 week
→ Oral valganciclovir (900 mg twice a day) 
for about 3 months
Subsequent RRD managed with vitrectomy, 
scleral buckling, photocoagulation, silicone 
oil tamponade
69 M DM CRVO PPV
IOL
4 0.1 0.2 Intravitreal ganciclovir (2 mg): not clearly 
disclosed in the article
Intravenous ganciclovir (5 mg/kg/12 hr) for 
1 week
→ Oral valganciclovir (900 mg twice a day) 
for about 3 months
Sekiryu et al. [4]
Jpn J Ophthalmol 
2008
63 M DM BRVO IOL 7 0.1 0.6 Intravenous acyclovir (prior to PCR result)
Intravenous ganciclovir 500 mg for 3 days
Oral ganciclovir for 1 week
Park et al. [5]
Korean J 
Ophthalmol 
2008
77 F HTN CRVO – 4 LP HM Intravenous acyclovir (prior to PCR result)
Intravitreal gancyclovir (1.7 mg)
Agon laser photocoagulation between 
retinitis and normal retina
After 3 weeks, aggravation
Repeated intravitreal gancyclovir (1.7 mg), 3 
times
This report 73 F DM
HTN
DME PPV
IOL
(OD)
3 0.1
(OD)
0.2
(OD)
Intravenous acyclovir for 7 days (prior to 
PCR result)
No anti-CMV treatment
IOL
(OS)
3 FC
30 cm
(OS)
0.1
(OS)
CMV = cytomegalovirus; IVTA = intravitreal triamcinolone acetonide; VA = visual acuity; DM = diabetes mellitus; DME = diabetic mac-
ular edmea; AMD = age related macular degeneration; IOL, cataract surgery; FC = finger count; CRVO = central retinal vein occlusion; 
PPV = pars plana vitrectomy; BRVO = branch retinal vein occlusion; PCR = polymerase chain reaction; HTN = hypertension; LP = light 
perception; HM = hand motion; OD = right eye; OS = left eye.153
WB Cho, et al. Spontaneous Resolution of CMV Retinitis after IVTA
nephropathy limited the use of acyclovir. Therefore, anti-
viral treatment was not started and the patient was closely 
monitored. A diagnostic aqueous humor sample for poly-
merase chain reaction (PCR) analysis was obtained. PCR 
was carried out to test for varicella zoster virus, herpes 
simplex virus type 1 and 2, and CMV. Topical anti-glauco-
matous and steroid medications were used for treatment.
The PCR results, available seven days later, confirmed 
the presence of CMV. The infectious disease consultant 
reported that systemic CMV infection was not possible 
and recommended antiviral therapy with ganciclovir for 
the CMV retinitis. However, one week had elapsed and the 
IOP and inflammatory reaction of the anterior chamber 
and vitreous had decreased, the peripheral retinal lesion 
did not increase, and the macula was not threatened in ei-
ther eye (Fig. 1C and 1D).
The CMV retinitis was likely caused by the local (intra-
ocular) immunosuppression caused by the IVTA and the 
immunosuppression might have reduced over time (already 
3 months since the IVTA was administered in both eyes). 
The CMV retinitis did not threaten the macula. Since start-
ing treatment with ganciclovir was not urgent, the patient 
was closely followed without any anti-CMV medications. 
The plan was close observation while maintaining the topi-
cal anti-glaucomatous and steroid therapy.
In November of 2008, two months after the initial pre-
sentation, the inflammatory reaction of the anterior cham-
ber appeared to be resolved and the vitreous haze was 
much improved in both eyes. The IOP was 24 mmHg in 
the right eye and 28 mmHg in the left eye with topical ap-
plication of timolol and dorzolamide. The necrotic retinal 
lesion regressed slightly without any progression of the 
margin of the lesion in both eyes.
In April of 2009, six months after initial presentation, 
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Fig. 1. (A,B) A 73-year-old woman, who 
underwent vitrectomy with intravitreal 
triamcinolone acetonide (IVTA) in the 
right eye and cataract surgery with IVTA 
in the left eye for bilateral diabetic macu-
lar edema, presented with visual loss in 
both eyes at three months post surgery. 
The fundus examination revealed white-
yellow, necrotic peripheral lesions in the 
superotemporal quadrant of both eyes. The 
clinical impression was bilateral acute reti-
nal necrosis. (C,D) Aqueous humor ana-
lyzed by polymerase chain reaction. The 
results were available seven days later and 
demonstrated the presence of cytomegalo-
virus. Meanwhile, despite no specific anti-
cytomegalovirus treatment, the peripheral 
retinal lesion did not progress, and did 
not threaten the macula in both eyes. The 
patient was followed closely. (E,F) Six 
months later, the retinal lesions regressed 
completely with subsequent development 
of pigmentary changes of both eyes. A 
mild vitreous haze was still present in the 
left eye.154
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the visual acuity was 40 / 200 in the right eye and 20 / 200 
in the left eye. The anterior chamber reactions had resolved 
and the inflammatory retinal lesions regressed completely 
with the subsequent development of retinal pigmentary 
changes in both eyes. A mild vitreous haze was still pres-
ent in the left eye (Fig. 1E and 1F).
Discussion
CMV is a ubiquitous infectious agent commonly found 
in the human population. Primary infection may produce 
mononucleosis-like symptoms. However, in immunocom-
petent individuals marked constitutional symptoms of in-
fection are rare. CMV infection occurs in 4% of live-born 
infants and 50% to 80% of adults. Moreover, PCR-based 
studies indicate that some seronegative adults are chronic 
virus carriers [9-12]. The site of chronic infection contin-
ues to be debated. Sites reported have included monocytes 
[9], bone marrow-derived myeloid progenitors such as 
granulocyte-macrophage progenitor cells [13,14], endothe-
lial cells and the smooth muscle cells of blood vessels [15-
18]. In murine studies, the possibility of the retina as a site 
of chronic infections has been proposed [19]. However, 
Vogel et al. [20] showed that the human eye (retina) is not 
a specific site for chronic CMV and that CMV retinitis is 
more likely due to infiltration of virus-infected circulating 
cells during immunosuppression. It is assumed that CMV 
spreads hematologically (in mononuclear and polymorpho-
nuclear leukocytes and/or endothelial cells) to infect the 
retina after reactivation [21,22]. Studies on patients with 
CMV retinitis have shown that retinal vascular endothelial 
cells can be infected with CMV in vivo. Therefore, it was 
assumed that CMV infected the retinal vascular endothe-
lial cells, leading to infection of the surrounding glial and 
neuronal cells followed by the retinal pigment epithelium 
[23].
Considering the wide use of IVTA, CMV retinitis could 
become a not-so-rare, significant complication attributable 
to local immunosuppression. The clinical course of the 
case reported here suggests that systemic treatment with 
ganciclovir may not be mandatory; its use should take into 
consideration such factors as host immunity, macular in-
volvement, the elapsed interval after IVTA, history of vit-
rectomy, and coexisting diabetic nephropathy, which can 
be aggravated by ganciclovir.
In previous reports, immunocompetent patients with 
CMV retinitis attributable to IVTA have been managed 
with intravenous ganciclovir similar to the treatment of 
immunocompromised patients (Table 1). However, the pa-
tient reported here was not treated with antiviral therapy. 
The IVTA-induced local (intraocular) immunosuppression 
was thought to decrease with time and that close observa-
tion without ganciclovir was appropriate in this patient; the 
intraocular concentration of triamcinolone is measurable 
for up to three months in the absence of a vitrectomy, and 
the elimination half-life would be much shorter in vitrecto-
mized eyes after IVTA [24,25].
Immunity plays a significant role in the pathogenesis 
of CMV retinitis in patients with acquired immunodefi-
ciency syndrome. Prior to the introduction of HAART, the 
treatment of CMV retinitis included an induction phase 
and maintenance phase with ganciclovir. Subsequently, 
prolonged use of ganciclovir was found to cause systemic 
adverse effects such as hematological abnormalities (neu-
tropenia, thrombocytopenia and anemia) and renal im-
pairment [26,27]. After the introduction of HAART with 
subsequent immune recovery, CMV retinitis may not recur 
even after maintenance anti-CMV therapy is discontinued. 
In addition, as this case illustrates, active CMV retinitis 
may spontaneously resolve in some patients that never re-
ceive specific anti-CMV treatment [28].
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